VF
DNTH icon

Virtu Financial’s Dianthus Therapeutics DNTH Stock Holding History

Virtu Financial’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,995
Closed -$390K – 1432
2024
Q1 		$390K Buy
+12,995
New +$282K 0.03% 511
2023
Q2 		– Sell
-670
Closed -$9K – 1625
2023
Q1 		$9K Buy
+670
New +$7.42K ﹤0.01% 1355
2022
Q4 		– Sell
-810
Closed -$18K – 1730
2022
Q3 		$18K Sell
810
-4,007
-83% -$110K ﹤0.01% 1417
2022
Q2 		$92K Buy
+4,817
New +$119K 0.01% 973

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Virtu Financial's DNTH Position: Q2 2024 in Review

Virtu Financial sold out of Dianthus Therapeutics (DNTH) in Q2 2024, closing a stake of 12,995 shares — an estimated $390K sold.

Virtu Financial first reported a position in DNTH in Q2 2022 and held it in 4 quarters. The position peaked at $390K in Q1 2024. 74 funds tracked by Wall St. Rank hold DNTH as of Q2 2024.

  • Virtu Financial reported no remaining Dianthus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Virtu Financial sold 12,995 Dianthus Therapeutics shares in Q2 2024, an estimated $390K.
  • Virtu Financial first reported a position in Dianthus Therapeutics in Q2 2022 and held it in 4 quarters.
  • Virtu Financial's Dianthus Therapeutics position peaked at $390K in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2024.

Based on Virtu Financial's 13F filing for Q2 2024, filed 9 Aug 2024.